Motor/Nonmotor Symptoms and Progression in Patients with Parkinson’s Disease: Prevalence and Risks in a Longitudinal Study

Figure 2

Daily levodopa dose and levodopa equivalent dose for DA based on age at each evaluation. (a) Daily dose of all 1227 patients included in this study, provided that at the last evaluation, the period of follow-up varied. (b) Daily dose of 445 patients who were followed up until the second evaluation. DA: dopamine agonists, LED: levodopa equivalent dose.

(a)

(b)